ArticleJournal of immunology (Baltimore, Md. : 1950)2026
Immunological evaluation of vaccines to prevent Chlamydia trachomatis infection using the human in vitro MIMIC system.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Modular Immune In vitro Construct (MIMIC) system is an established laboratory-based methodology that reproduces in vitro the human in vivo T-cell immune response. In this study, we utilized the MIMIC system to establish a dendritic cell and CD4+ T-cell co-culture model that recapitulates T helper cell responses to Chlamydia trachomatis infection in humans. We demonstrate that C. trachomatis infection induces C. trachomatis-specific IFN-γ-producing CD4+ T-cell responses, with IFN-γ as the dominant cytokine, accompanied by significant production of TNF-α, IL-13, IL-8, and IL-6. Live C. trachomatis induces stronger IFN-γ CD4+ T-cell responses than heat-killed bacteria. A C. trachomatis outer membrane protein vaccine comprising the major outer membrane protein and polymorphic membrane proteins PmpE, PmpG, and PmpH elicited limited CD4+ T-cell responses, while an attenuated Chlamydia muridarum whole cell-based vaccine (intrOv) generated robust CD4+ T-cell responses against C. trachomatis challenge, encompassing multiple genital C. trachomatis serovars. The results suggest that intrOv vaccine should advance along the clinical development pathway as a chlamydia vaccine. MIMIC represents a valuable platform for evaluating chlamydia vaccine candidates, and it can reduce time and cost required to advance vaccine candidates to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.